Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Potassium-Retaining Diuretics: Amiloride
Biomarkers for Brain Disorders: Challenges and Opportunities
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
Prevention and treatment of MS: studying the effects of vitamin D.
A high-density screen for linkage in multiple sclerosis.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
Substance Name: Amiloride
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Receptos Reports Positive Phase 2 Results for TOUCHSTONE Trial of RPC1063 in Ulcerative Colitis
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results.
Prolonged Remission in Neuromyelitis Optica Following Cessation of Rituximab Treatment.
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
Cardiotoxicity of mitoxantrone treatment in a german cohort of 639 multiple sclerosis patients.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
US top court denies Israel's Teva Pharmaceuticals stay in Copaxone patent fight
Laquinimod

Pages